Dupin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dupin

Property Description
Active ingredient Diazepam
Form Tablet, Oral Solution, Injectable Solution
Pharmacological class Benzodiazepine
General purpose Reducing excessive neurological activity
Origin Synthetic compound

What Type of Medicine Is Dupin? (Classification and Origin)

Dupin is a synthetic psychotropic medication whose active component is Diazepam, classified as a benzodiazepine. This compound is not naturally occurring; it is a chemically synthesized substance that interacts directly with the central nervous system (CNS). This class of medicine is recognized for its capacity to reduce central neural overactivity. Diazepam is a benzodiazepine derivative chemically related to chlordiazepoxide. Dupin is manufactured as a single-ingredient product, offering the specific, long-acting profile characteristic of Diazepam.


Composition and Available Forms of Diazepam

The core composition of Dupin utilizes Diazepam alongside various pharmaceutical excipients suitable for its intended delivery method. Diazepam is prepared in several essential dosage forms. These preparations include the standard tablet for oral administration and the oral solution. Furthermore, its availability as an injectable solution for both intravenous and intramuscular routes, in addition to specialized preparations like the rectal gel and suppository, differentiates it. This wide range of forms allows for the versatile management of acute situations, such as the rapid intervention required in managing generalized muscle stiffness.


General Purpose and Mechanism of Action (High-Level)

The general purpose of Dupin is to provide a comprehensive CNS depressant effect, reducing excessive and uncontrolled electrical activity within the central nervous system. This is achieved through the drug's mechanism of enhancing the function of the body's main inhibitory neurotransmitter, GABA (gamma-aminobutyric acid). Its effectiveness in reducing neurological hyperexcitability is the foundation of its general benefits. These benefits include the capacity to diminish states of intense psychological tension, the stabilization of abnormal neurological firing often associated with acute disturbances, and the relaxation of involuntary skeletal muscle spasms.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Dupin?

Possible Side Effects and Safety Information

The official safety profile for Dupin (Diazepam) is structured around its primary effects on the Central Nervous System (CNS), as documented in regulatory sources such as the FDA and EMA. Adverse reactions are grouped by System-Organ-Class and frequency.

Common and Expected Adverse Reactions

The most frequent adverse reactions are generally classified as Common and often occur at the start of treatment, potentially diminishing with continued administration. These typically include CNS effects such as drowsiness, fatigue, somnolence, reduced alertness, and ataxia (impaired coordination). Other common effects may involve muscle weakness.


Serious Adverse Reactions and Key Constraints

Regulatory documentation highlights serious but less common adverse reactions and critical safety constraints:

  • Respiratory Risk: The label includes a Boxed Warning regarding the co-administration of Dupin with opioids, which may result in profound sedation, respiratory depression, coma, and death.
  • Dependence and Withdrawal: The medication carries a risk of developing physical and psychological dependence with long-term exposure, leading to potentially severe withdrawal symptoms upon abrupt discontinuation.
  • Paradoxical Reactions: Rarely, reactions such as agitation, aggression, and hostility may occur.

Population-Specific Safety Considerations

Safety constraints apply to specific populations. Older adults may be more susceptible to the CNS depressant effects, increasing the risk of confusion and falls. Dupin is contraindicated in patients with conditions such as severe hepatic (liver) insufficiency and severe respiratory insufficiency. It is also not recommended for use in infants under 6 months.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Dupin is formally documented by regulatory authorities, focusing strictly on manifestations and required emergency actions.

Property Official Regulatory Statement
Documented overdose presentations The primary manifestation is Central Nervous System (CNS) Depression, presenting with signs that include drowsiness, confusion, ataxia (uncoordinated movement), and slurred speech. Severe states may progress to stupor or coma.
Physiological systems affected The overdose affects the CNS and the Respiratory System. Hypotension is also documented, particularly in cases of severe overdose.
Dose-related or exposure-related factors The risk of respiratory depression and death is significantly increased when coingestion occurs, especially with opioids or alcohol.
When immediate medical help is required Seek emergency medical attention immediately upon suspected overdose. Contacting emergency services or the Poison Control Center is mandated in regulatory instructions.

The official management strategy is primarily supportive care involving continuous monitoring of vital signs and, where necessary, providing breathing support or mechanical ventilation for respiratory compromise. Flumazenil, a specific antidote, is documented for the potential reversal of the drug’s sedative effects. This profile strictly defines the severe, life-threatening outcomes that may occur and dictates that the only appropriate course of action is to seek immediate professional medical management as specified in the official labeling.

Therapeutic Uses of Dupin

What Dupin Treats: Main Uses and Benefits

This medication is commonly used across domains where additional symptomatic support is needed, generally providing support that helps ease the overall symptom burden. It is applied in contexts marked by increased discomfort or tension, assisting with maintaining functional stability when symptoms interfere with routine activities.

Dupin is relevant for easing symptoms of severe anxiety and acute agitation, addressing skeletal muscle spasms, and providing supportive relief in both convulsive episodes and acute alcohol withdrawal syndromes. The intent of this use is symptomatic relief. The medication is applied in situations requiring temporary assistance in symptom stabilization.

Quick Fact: Symptomatic Support for Heightened Tension

Dupin is applied in clinical settings that involve acute or unstable symptom patterns, addressing symptoms of increased neurological or muscular activity. It supports patients during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Dupin (Diazepam) eligibility is strictly defined by regulatory bodies to exclude certain populations where the risks are deemed unacceptable. The medicine is contraindicated in patients diagnosed with Myasthenia Gravis, severe hepatic insufficiency (severe liver disease), severe respiratory insufficiency, or sleep apnea syndrome. It is also prohibited for patients with acute narrow-angle glaucoma or known hypersensitivity to the drug.

Age is a primary factor determining use. The medicine is contraindicated in pediatric patients under 6 months of age due to insufficient clinical experience. Older adults (geriatric patients) often require careful monitoring, as regulatory guidance suggests that long-acting benzodiazepines like Diazepam are generally not recommended for this population.

Use is generally not recommended during pregnancy or breastfeeding because the drug and its metabolites are known to cross into breast milk. Furthermore, caution is required for individuals with a history of alcohol or drug abuse, and use is restricted in those with chronic respiratory conditions or mild to moderate hepatic impairment, even if the severe condition is not present.

What should I know about interactions with other medicines?

Dupin Interactions with Other Medicines and Products

Official regulatory documents define the interaction profile of Dupin (Diazepam) based on effects related to CNS depression and changes in drug clearance. This section details officially documented interaction information.

Documented Pharmacodynamic Interactions

Co-administration with substances that also depress the central nervous system (CNS) results in additive or synergistic effects, including enhanced sedation and respiratory depression. This applies to several medicinal product categories, including other anxiolytics, hypnotics, antipsychotics, narcotic analgesics, and sedative antihistamines. For instance, the combination of Dupin with Opioids is subject to a regulatory restriction and a Boxed Warning due to the severe risks of profound sedation, respiratory depression, coma, and death.

Interactions Affecting Clearance (Pharmacokinetic)

Dupin is metabolized through specific liver enzymes, primarily CYP2C19 and CYP3A4. Interactions are categorized as follows:

Interaction Type Examples (Official Documentation) Documented Effect on Dupin
Inhibitors Cimetidine, Fluoxetine, Fluvoxamine, Ketoconazole Decrease elimination rate, potentially increasing exposure and sedation
Inducers Rifampin, Carbamazepine, Phenytoin Increase elimination rate, potentially reducing Dupin concentration and effect

Co-administration with potent inducers, such as Rifampin, should be avoided due to substantial increase in clearance. Other interacting medicines, such as Sodium Valproate, are documented to increase Dupin serum levels via displacement from protein-binding sites.

Other Documented Interactions and Constraints

Simultaneous ingestion of Alcohol is explicitly advised against due to the risk of enhanced CNS depressant effects. Additionally, taking oral Dupin with a moderate-fat meal is documented to delay and decrease its absorption. Specific population groups, such as the Elderly or patients with Chronic Hepatic Disease, may experience altered drug clearance that heightens the relevance of these interactions.

Mechanism of Action

How Dupin Works

Targeting the Interleukin-4 Receptor Alpha

Dupin functions as a highly specific monoclonal antibody antagonist that targets the Interleukin-4 receptor alpha (IL-4Ralpha) subunit found on the surface of various immune and non-immune cells. By binding to this receptor, Dupin physically blocks the specific recognition site required for two key inflammatory messengers, Interleukin-4 (IL-4) and Interleukin-13 (IL-13). This action inhibits the ligands, IL-4 and IL-13, from triggering their subsequent intracellular signaling events.


Modulating the Type 2 Inflammatory Pathway

Prevention of IL-4 and IL-13 signaling consequently influences the entire Type 2 inflammatory pathway. This mechanistic suppression modifies the early molecular steps that drive the generation of specific immune cell types and mediators, such as Immunoglobulin E (IgE). The resulting effect is an altered activity profile within the targeted inflammatory cascade.


Systemic Physiological Modulation

Consistent reduction of Type 2 inflammatory signaling influences the downstream effects of elevated mediator activity, resulting in a shift away from high-level pathway activation in peripheral tissues. This mechanism involves the modulation of specific pathway components, resulting in defined physiological adjustments that comprise the drug's overall mechanistic profile.

Dosage and Administration Information

Dupin (Diazepam) is administered through several officially approved routes, depending on the required speed of action and clinical setting. Oral forms, such as tablets and solution, are used for scheduled, long-acting use, typically administered two to four times daily. The tablets and liquid may be taken with or without food. If using the liquid concentrate, it should be mixed with water or soft food and consumed immediately.

For rapid intervention, the medicine is administered parenterally via Intravenous (IV) or Intramuscular (IM) injection, or through specialized rectal gel or intranasal spray formulations. The IV route is subject to strict procedural constraints: the solution must be injected slowly, at a rate not exceeding 5 milligrams per minute, and should not be mixed or diluted in the syringe with other solutions. The use of the rectal gel for seizure clusters is limited to no more than 1 episode every 5 days and a maximum of 5 episodes per month.

Official dosing instructions mandate that older adults and patients with hepatic or renal impairment must be started on the lowest possible initial dose (e.g., 2 mg to 2.5 mg) and increased gradually. For anxiety, the overall treatment duration should be the shortest possible, generally not exceeding 8 to 12 weeks, including a period of gradual dose reduction (tapering). Abrupt discontinuation is not recommended. If an oral dose is missed, it is recommended to skip the missed dose and continue the regular schedule; double doses must not be taken.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dupin (Diazepam)

Evidence for Use in Acute Convulsive Episodes

The research investigating Dupin's evaluation in acute convulsive episodes, such as status epilepticus, primarily consists of short-term, controlled clinical trials and regulatory reviews. These studies were conducted in emergency and pre-hospital settings and research focused on immediate outcomes, such as the timing of seizure cessation. The study populations included both adults and pediatric populations presenting with these acute and disruptive episodes. Findings described patterns related to the timing of seizure cessation observed in these time-critical scenarios.

Evidence for Use in Severe Anxiety and Acute Agitation

The evaluation for severe anxiety was conducted through controlled investigations, including double-blind studies comparing the medicine to a placebo. These trials were relevant in research assessing short-term or episodic symptom patterns and often explored symptom changes over the course of a few weeks. Research examined outcomes related to physical discomfort and changes in standardized anxiety rating scales. The evidence is focused on outcomes measured during short-term use, and long-term evaluation remains uncertain.

Evidence for Use in Skeletal Muscle Spasm and Alcohol Withdrawal

For skeletal muscle spasm, the evidence often comes from Systematic Reviews and comparative trials that studied the medicine as an adjunct (supportive) therapy. Research examined outcomes reflecting daily functioning and measures of muscle hypertonicity. For Alcohol Withdrawal Syndrome, evidence relies on regulatory clinical reviews and historical controlled trials. Research described measurements indicating an alteration in withdrawal symptom severity scores during the acute phase of withdrawal.

What is Still Uncertain About Dupin's Evidence

Key limitations include that the sample sizes were modest in some of the older trials, and evidence quality varies across studies, particularly for long-term symptom management. Comparative evidence against all newer agents in every indication is sometimes lacking. Furthermore, findings describe group patterns, not personal outcomes, meaning research does not determine whether an individual will respond similarly to the results observed in the study.

Key Studies & References

  1. Guideline for Treatment of Prolonged Seizures in Children and Adults
  2. Efficacy of diazepam as an anti-anxiety agent: meta-analysis of double-blind, randomized controlled trials carried out in Japan

Frequently Asked Questions (FAQ)

Common questions about Dupin (FAQ)

Q: What is Dupin primarily used for according to official documents?

Official regulatory documents state that Dupin (Diazepam) is approved for several uses. These include the management of anxiety disorders, providing relief from acute alcohol withdrawal symptoms, and being used as an additional treatment for skeletal muscle spasms and certain convulsive disorders.

Q: How quickly can someone generally expect Dupin to start working?

The onset of effects depends on the form of Dupin being administered. For oral forms, the medicine typically reaches its peak concentration in the body within 1 to 1.5 hours. For formulations used in rapid intervention, such as intravenous administration, the effects may begin to be noticeable within minutes.

Q: Does Dupin interact with common over-the-counter pain relievers?

Official warnings focus on the risk of additive effects when Dupin is combined with Central Nervous System (CNS) depressants. This category can include certain over-the-counter cough and cold medicines, such as those that contain sedating ingredients like diphenhydramine. Combining these products may intensify the depressant effects.

Q: Is it necessary to avoid certain foods or drinks while using Dupin?

Yes, regulatory documents explicitly advise against consuming alcohol while using Dupin due to the risk of enhanced Central Nervous System (CNS) depressant effects. Furthermore, official warnings state that the ingestion of grapefruit and grapefruit juice may interfere with how the drug works in the body.

Q: Can Dupin cause weight changes?

Changes in weight are not commonly listed as frequent side effects in major regulatory documents. However, some patient-focused information indicates that Dupin may rarely influence a person's appetite.

Q: Is Dupin considered appropriate for use in older adults?

Official guidance recommends that older adults be started on the lowest possible initial dose. This is because they may be more susceptible to Central Nervous System (CNS) depressant effects, which increases the potential for confusion and falls. The need for careful monitoring is often noted for this population.

Q: Does Dupin have a 'Boxed Warning' from the FDA?

Yes, the official FDA label for Dupin includes a Boxed Warning, which highlights serious safety concerns. This warning is specifically focused on the risk of profound sedation, respiratory depression, coma, and death when Dupin is used at the same time as opioid medicines.

Q: Are there specific medical tests required before starting Dupin?

Official regulatory precautions state that a healthcare provider will monitor the patient's progress at regular visits. To check for any potential unwanted effects related to the drug's metabolism, blood tests may be a component of the regulatory precaution.

Q: Does Dupin interact with supplements like vitamins or herbal products?

Official warnings advise that some herbal supplements can interact with Dupin, particularly those that have a known sedative effect, such as kava or valerian. Combining these types of supplements may intensify the drug's own sedative effects, according to regulatory sources.

Q: Is it true that Dupin can cause a metallic taste?

While not consistently listed as a frequent adverse reaction in major regulatory documents, this effect falls into a general category of drug-induced changes that may occur, although it is not consistently listed as a frequent reaction.

Q: Can Dupin be taken alongside medicines for high blood pressure?

Official information suggests caution when Dupin is taken alongside certain medicines for high blood pressure (antihypertensives). The combination may have additive effects in lowering blood pressure, which can increase the risk of symptoms like dizziness and fainting.

Q: Is Dupin used to prevent a condition from getting worse?

According to official indications, Dupin is primarily used for the short-term relief of symptoms associated with acute conditions, such as anxiety, muscle spasms, and certain convulsive episodes. It is generally not intended for use as a long-term preventative treatment.

Q: Are there any known issues with Dupin and vision changes?

Yes, official information indicates that potential ocular side effects may include blurred vision and dry eyes. It is also important to note that Dupin is contraindicated, or officially prohibited, for use in patients with acute narrow-angle glaucoma.

Q: How long does Dupin stay in the system after the last use?

Dupin (Diazepam) has a relatively long elimination profile. The drug itself has a terminal elimination half-life of up to 48 hours. Furthermore, it is converted into an active metabolite in the body which can have an even longer half-life, lasting up to 100 hours.

Q: Can Dupin cause skin reactions or rashes?

Yes, official patient information lists skin rash as a potential side effect of Dupin. Official guidance indicates that signs of a serious allergic reaction, such as a severe or blistering rash, should be evaluated by a healthcare professional.

Q: What is the regulatory status of Dupin in the United States?

In the United States, Dupin (Diazepam) is officially classified as a Schedule IV (CIV) Controlled Substance by the Drug Enforcement Administration (DEA). This classification reflects that the drug has a recognized medical use while noting a potential for abuse or dependence.

Q: Has Dupin been subject to any major safety alerts?

The most significant mandatory safety alert related to Dupin is the FDA Boxed Warning. This warning highlights the critical risk of profound sedation, respiratory depression, coma, and death when Dupin is used in combination with opioid medications.

Q: Does Dupin require any special monitoring like blood tests?

Yes, due to its metabolism and potential unwanted effects, regulatory precautions note that blood tests may be required at regular visits.

Q: Is Dupin known to cause headaches or migraines?

Headache is listed as a potential mild side effect that was reported in clinical studies of Dupin (Diazepam).

Q: What is the official definition of the condition Dupin is used to treat?

Dupin is officially categorized as a Central Nervous System (CNS) depressant. It works by enhancing the calming effects of the GABA neurotransmitter, thereby reducing excessive and uncontrolled electrical activity in the nervous system.

Q: Can Dupin affect a person's ability to drive or operate machinery?

Yes, due to the potential for side effects such as sedation, drowsiness, and reduced alertness, regulatory information advises caution. Patients are generally advised not to drive or operate heavy machinery until they understand how the medication affects their coordination and reaction time.

Q: What happens to Dupin in the body over time?

Dupin is considered a long-acting medicine that is absorbed after oral administration and then extensively metabolized by the liver. The drug is converted into active metabolites, which are compounds that continue to exert effects, contributing to the prolonged duration of the drug's activity in the body.

Q: What are the components of Dupin (active and inactive ingredients)?

The single active ingredient in Dupin is Diazepam. The finished medicine also contains various inactive ingredients, known as excipients, which help form the tablet or solution. Inactive ingredients for the tablet form often include items such as corn starch, anhydrous lactose, and magnesium stearate, though specific dyes may vary by strength.

How should Dupin be stored and disposed of?

How to Store and Dispose of Dupin?

Dupin (Diazepam) must be stored in accordance with official labeling to ensure stability and safety, particularly regarding child access.

Official Storage Requirements

Condition Requirement Details
Temperature Controlled Room Temperature 20 C to 25 C (68 F to 77 F)
Protection Protect from light, moisture, and freezing Keep in a dry place; avoid extreme heat.
Container Tightly closed container The Oral Solution must be dispensed in a light-resistant container.
Child Safety Secure storage required Keep out of the sight and reach of children.

Stability and Disposal

The Oral Solution Concentrate must be discarded 90 days after the bottle is opened. Any solution that is diluted or mixed for administration must be taken immediately and cannot be stored for later use. For disposal of unused or expired Dupin, patients should utilize official drug take-back programs. If these programs are unavailable, follow regulated guidelines for household trash disposal, which involves mixing the drug with an undesirable substance before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dupin found in:

A-Z Index: